



TAG

Treatment Action Group

2018 TAG ANNUAL REPORT

PROGRESS IN THE FIGHT

For Better Treatment, Prevention,
A Vaccine, and a Cure for HIV,
Tuberculosis, and Hepatitis C Virus

June 17, 2019


Dear Friend of TAG:

I'm thrilled to share with you TAG's 2018 *Annual Report*. Here you will see how TAG's effective, tenacious activism has battled with a political climate replete with obstacles and barriers and destructive policies to defend and expand U.S. funding for international and domestic efforts to fight HIV, hepatitis C virus (HCV), and tuberculosis (TB).

TAG won significant victories in 2018, including expanded support for research conducted by the U.S. National Institutes of Health, the domestic AIDS Drug Assistance Programs and the international efforts to fight AIDS and TB, the endorsement by the World Health Organization and the United Nations General Assembly of ambitious targets for TB research and programs, the launch of a historic HCV elimination strategy and task force by New York State, and measurable progress against the HIV and TB epidemics in New York City and New York State.

Your support makes all our work possible. In the coming year we'll continue to fight to build evidence, programs, strategies, and alliances to bring the end of these three epidemics closer than ever. From the bottom of our hearts, I and everyone on TAG's board and staff – and on behalf of the communities our advocacy serves to preserve their health and lives – thank you for all the work that your support makes possible!

Yours truly,




Barbara Hughes
President, Board of Directors

“Your support makes all our work possible. In the coming year we’ll continue to fight to build evidence, programs, strategies, and alliances to bring the end of these three epidemics closer than ever.”

2018 RESEARCH IN ACTION AWARDS

TAG's 2018 Research in Action Awards took place on November 15 at Slate in New York City, and honorees were: Masha Gessen; Margaret Hamburg, MD; Joy Tomchin; and Jenna Wolfe, who received a Lifetime Friend of TAG award. The event honors activists, scientists, philanthropists, and creative artists who have made contributions to the fight against HIV, tuberculosis, and hepatitis C virus. Resources raised at RIAA provide vital support for TAG's programs throughout the year.



Event co-host Ann Northrop gave a moving reading of Zoe Leonard's *I want a president*.



TAG ED Mark Harrington, with honoree Joy Tomchin.



Honoree Masha Gessen, accepting her award via Skype.



UNITED's Jim Aquino and Bob Bronzo talked about why they and their friends, UNITED, donate to TAG.



Paul Katz of the Marta Heflin Foundation (an RIAA sponsor), with Barbara Hughes, TAG Board President.



Honoree Peggy Hamburg on stage.

TAG ANNUAL REPORT PROJECT UPDATES

HIV PROJECT

In 2018, TAG furthered Ending the Epidemic (EtE) success in New York. Recent reports from New York City and State showed that new HIV infections are beginning to decline due to the state's EtE strategy. To share best practices and lessons learned from New York with the rest of the country and world, TAG launched a series of online EtE modules. In partnership with Housing Works, TAG created the first EtE University, at which representatives from the hard-hit southern United States convened to learn and plan for launching EtE plans in their jurisdictions. This support helped spur EtE movements in Alabama, Louisiana, and Nashville, Tennessee. The Act Now, End AIDS coalition, which TAG co-convenes, drove the drafting of a national EtE plan that launched on World AIDS Day 2018, and which will underpin much important advocacy and accountability for ongoing U.S. government efforts to combat HIV around the country.

TAG's role leading evidence-based advocacy around HIV basic science, vaccines, and cure placed our work at the forefront of many important discussions in 2018. Richard Jefferys' longstanding work on gene editing poised TAG to respond quickly, knowledgeably, and powerfully to troubling news: TAG decried the report from researcher He Jiankui of twins born from embryos whose genes he had unethically edited using CRISPR technology for the HIV co-receptor CCR5. TAG delved into implications of HIV cure-related trials involving interruptions of antiretroviral therapy for a research summit, to ensure community perspectives were incorporated. TAG advocated for appropriate therapeutic interventions for people who, despite HIV treatment, still have poor immune reconstitution. Our HIV Cure Clinical Trials website listing, updated monthly, has become a central resource for researchers and partners seeking information on cure studies and their results.

TAG's deep understanding of science also underpins our effective policy and anti-discrimination work.

Armed with the knowledge of the myriad ways to effectively treat and prevent HIV, TAG's Jeremiah Johnson led an advocacy campaign to confront the Peace Corps regarding its poor policies on HIV treatment, care, and prevention. The Peace Corps had discriminated against Jeremiah in 2008 when it kicked him out of his Peace Corps posting in Ukraine for testing positive for HIV. That the same discrimination would resurface a decade later, with two volunteers ejected in 2018, catalyzed a successful campaign by Jeremiah and other U.S. HIV policy organizations. One volunteer resumed service; the other has decided to stay in the U.S. for the time being. The Peace Corps committed to increase the list of host countries where HIV positive volunteers can serve, and opened the lines of communication for ongoing discussions on ways to improve their HIV policies.

In 2018, TAG's HIV team published the following publications:

- *TAG Issue Brief: Suboptimal Immune Recovery on Antiretroviral Therapy*
- *Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults*
- *The Antiretroviral Pipeline*
- *The HIV PrEP and Microbicides Pipeline*
- *The HIV Vaccines, Passive Immunization, and Antibody Gene Transfer Pipeline*
- *The Research Toward a Cure and Immune-Based Therapies Pipeline*
- *Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research* (TAGline December 2018)
- *Bend the Curves: Activism and the Elimination of HIV, HCV, and TB* (TAGline April 2018)
- *The Usual Suspects: Common Challenges for EtE Planning and Implementation in Emerging Jurisdictions* (TAGline April 2018)
- *New York State EtE Campaign Update: Successes & Challenges* (TAGline April 2018)
- *The Role of Vaccines and Cures in HIV Elimination* (TAGline April 2018)

HEPATITIS C VIRUS (HCV) PROJECT

Among TAG's biggest victories in 2018 was advocacy to secure Governor Cuomo's commitment to eliminate HCV in New York State. The result of a lengthy budget and policy advocacy campaign led by TAG's Annette Gaudino, this commitment made New York the first state in the nation to commit to ending HCV. Governor Cuomo's announcement included a two-year commitment to quadruple program funding for HCV, and the commission of a statewide HCV Elimination Task Force, to which Annette was appointed. In New York City, TAG advocated successfully for increased funding for peer HCV prevention, testing, linkage to care, and treatment support.

With the advent of simple, highly effective cures for HCV, elimination can and should be the goal everywhere. But poor access to screening and testing remains a barrier. Awareness, improved treatment and diagnostics literacy, and capacity building in advocacy are key to supporting scale up of HCV diagnosis and treatment access. As such, TAG – with new support from the Foundation for Innovative New Diagnostics (FIND) – launched an HCV diagnostics advocacy training and support project. Bryn Gay is leading this work, which includes targeted trainings in Georgia and Malaysia, and technical assistance for activists in Cameroon, India, Myanmar, and Vietnam.

Our global HCV work includes broader community mobilization to address structural barriers to care.

Recognizing the importance of addressing the disproportionate burden of HCV in migrant communities, TAG co-convened with the European African Treatment Advocates Network and other migrant-focused organizations the European African HIV and HCV Community Summit. Held just before the AIDS 2018 conference in Amsterdam, the Summit developed strategies to make the best treatment and diagnostics accessible for all, and to ensure that national elimination plans include policies supporting the health and rights of migrants.

To support this work, TAG's HCV team published the following publications:

- *Training Manual for Treatment Activists, Hepatitis C Virus & Coinfection with HIV* (available in English, French, and Spanish)
- *The HCV Diagnostics Pipeline*
- *The HCV Treatment Pipeline*
- *Fierce Activism from the Global Access to Medicines (A2M) Movement: Reflections on Recent Success* (TAGline December 2018)
- *Getting Rid of the Boogeyman: The Reality of Prescription Drug Price Controls* (TAGline December 2018)
- *Pharma Lies, People Die: Myth-Busting Fact Sheet on Medicine Development and Pricing* (TAGline December 2018)
- *It's up to You, New York: Moving towards HCV Elimination in the Empire State* (TAGline April 2018)
- *Global HCV Elimination Targets and Challenges: An Interview with Andrew Hill* (TAGline April 2018)

TUBERCULOSIS (TB) PROJECT

2018 was a momentous year for the global fight against tuberculosis. The United Nations General Assembly held its first-ever High-Level Meeting on TB. TAG's work in the lead up to the event centered on

securing commitments for investing in TB research and development (R&D) and equitable access to the fruits of those investments. TAG's work continued to focus on neglected populations, including people with HIV and TB co-infection, and children – who make up 10% of TB cases globally, yet are too seldom included in either research or programs. Erica Lessem organized and Mike Frick presented at a briefing for UN missions on TB R&D. Suraj Madoori organized meetings

“2018 also saw the culmination of years of advocacy to encourage the uptake of newer, more effective, less toxic treatment options for TB.”

between the U.S. mission and the U.S. civil society delegation to advance priorities for both global and domestic TB elimination.

TAG's TB and policy teams advanced a novel approach laying out “fair share” targets by which each country dedicates 0.1% of its overall spending on research to TB research in particular, which would close the global TB R&D funding gap. The resultant Political Declaration from the High-Level Meeting itself endorsed a goal of ensuring that each country contributes appropriately to TB R&D. Thanks to Lindsay McKenna's tireless advocacy in collaboration with partners, pediatric commitments made it into the Political Declaration.

TAG's TB work draws upon Mike Frick's extensive work analyzing TB R&D investments over more than a decade and his efforts to advance the human right to enjoy the benefits of scientific progress and its applications. In 2018, the latter featured several submissions to UN bodies, including a presentation to the UN Committee on Economic, Social and Cultural Rights, which will inform the first authoritative interpretation of the right to science, expected later in 2019.

While New York City hosted the UN General Assembly meeting, it was also abuzz with its own response to a growing local TB problem. After over a decade of chronic under-investment in New York City's TB response, exacerbated by a fresh budget cut from New York State, TB cases in New York City grew substantially in 2017 for the first time in two decades. This worrying trend jumpstarted TAG into action to quickly convene an activist coalition of New York based organizations working on immigration, homelessness, and other health and vulnerable population issues. This coalition rallied political and media attention, and resulted in restoring \$2.4 million in funding for New York City's TB program, which allowed for reinstatement of staff positions and for clinics to remain open.

2018 also saw the culmination of years of advocacy to encourage the uptake of newer, more effective, less

toxic treatment options for TB. TAG and collaborators successfully encouraged the World Health Organization to update its drug-resistant TB guidelines, resulting in recommendations for a safer, more effective standard of care based on newer drugs including bedaquiline. While the recommendations still require improvement, they are nonetheless a major step forward in ensuring people will no longer be subjected to painful injections or hearing loss from toxic, less effective older TB medicines. To help promote uptake of bedaquiline in the U.S., TAG, the National TB Controllers Association, and Johns Hopkins University led a successful campaign to reduce access barriers, including improvements to the patient assistance program to ease free access, and a commitment from the manufacturer for packaging better suited to the needs of TB programs and patients.

TAG's prolific TB team issued multiple publications to advance these advocacy initiatives:

- *Know Your Rights Guide: Tuberculosis Prevention, Diagnosis, and Treatment* (available in nine languages)
- *Is Shorter Better? Understanding the Shorter Regimen for Treating Drug Resistant Tuberculosis*
- *The Vital Role of Research for TB Elimination*
- *An Activist's Guide to Bedaquiline*
- *Reality Check: The Price of Bedaquiline*
- *Tuberculosis Research Funding Trends, 2005-2017*
- *Funding for TB Research – Recent Momentum Must Inspire Bold Commitments*
- *The Pediatric Tuberculosis Pipeline*
The Tuberculosis Diagnostics Pipeline for Children
The Tuberculosis Prevention Pipeline for Children
The Tuberculosis Treatment Pipeline for Children
- *The Tuberculosis Prevention Pipeline*
- *A Pharma View on Delinkage and New Models for Biomedical Innovation: An Interview with Marc Destito From Otsuka Pharmaceutical* (TAGline December 2018)
- *The United Nations' Back Yard: TB Elimination in New York State and the U.S.* (TAGline April 2018)
- *From Moscow to New York and Beyond: The Future of Tuberculosis Research and Development* (TAGline April 2018)

U.S. AND GLOBAL HEALTH POLICY

TAG's U.S. and Global Health Policy team supported and were instrumental to advancing many of the previously mentioned initiatives. With coordination from Suraj Madoori, TAG staff wrote many sections of the above-mentioned community-driven National EtE Plan to reflect needed priorities to address HIV, as well as HCV and TB.

Drug pricing and access was central to TAG's work, and remains so with an explosion of political attention in 2019. In 2018, TAG helped prepare allies for this work by creating and leading many sessions at the Affordable Medicines Now Conference, which was the first conference dedicated to providing a space for U.S.-based access-to-medicines activists to tackle issues from intellectual property abuses to extortion drug pricing. TAG ramped up its legislative engagement to promote access and lower drug prices: Suraj Madoori and external partners successfully fended off an amendment to the Pandemics and All-Hazards Preparedness Act known as the Re-Valuing Anti-Microbial Products Act of 2018, which would have created transferable monopolies for developers of antimicrobials, while failing to provide any access requirements for resulting products.

Another legislative advance in 2018 was the inclusion of TB priorities in the Health Equity and Accountability Act by the Congressional Black Caucus, Hispanic Caucus, and Asian Pacific Islander Caucus. TAG and partners secured a \$15 million increase for USAID's TB program for fiscal year 2018 – the biggest federal TB increase in years, and fended off the President's cuts for domestic HIV and viral hepatitis. TAG protected funding for U.S. Centers for Disease Control and Prevention (CDC)'s domestic TB elimination, while advancing the Comprehensive TB Elimination Act, which would authorize funding for five years for the CDC's domestic TB response and global TB research.

TAG was active at resisting mounting threats to foreign-born Americans, which would undermine their human rights as well as their and the broader public's health. Annette Gaudino and Erica Lessem spent a night in jail for civil disobedience in response to a draft rule that would dramatically redefine a "public charge," deterring many from seeking key treatment and prevention for HIV, HCV, TB, and other health conditions out of fear of becoming ineligible for immigration status adjustments (e.g., getting a green card). TAG joined many community groups in opposing the addition of a citizenship question to the Census; TAG's public comment explained how such an addition could discourage participation and lead to inequities in the allocation of federal resources.

“ Drug pricing and access was central to TAG's work, and remains so with an explosion of political attention in 2019. ”

Some key TAG policy publications from 2018 that advanced our work include:

- *United to End Tuberculosis: Key Asks for the U.S. from TB Stakeholders and Communities*
- *Ending Exemptions from the Pediatric Research Equity Act (PREA)*
- *Whose Intellect? Whose Property? A Blueprint for Bringing Down the Pharma IP House of Cards* (TAGline December 2018)
- *Beyond Declarations: Lessons from the UN High-Level Meeting on TB on Building and Transforming Political Will into Real Access to Medicines* (TAGline December 2018)
- *In a State of Disunion: HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration* (TAGline April 2018)

Balance Sheet

	2018	2017
Assets		
Cash and cash equivalents	\$1,534,231	\$1,949,112
Unconditional Promises to Give	1,216,871	1,549,894
Accounts receivable	1,139	
Prepaid expenses and other current assets	31,594	25,384
Donated artwork	439,739	414,500
Security deposit	72,463	72,463
Property and equipment - net	26,728	25,974
Total assets	\$3,322,765	\$4,037,327
Liabilities and Net Assets		
Liabilities		
Accounts payable and accrued expenses	\$25,396	\$25,660
Deferred rent	\$42,520	55,069
Total liabilities	67,916	80,729
Net assets		
Without donor restrictions	1,736,034	1,907,539
With donor restrictions	1,518,815	2,049,059
Total net assets	3,254,849	3,956,598
Total Liabilities and Net Assets	\$3,322,765	\$4,037,327


Statement of Cash Flows

	2018	2017
Cash Flows from Operating Activities		
Adjustments to reconcile increase (decrease) in net assets to net cash used by operating activities:		
Depreciation	(\$701,749)	\$1,438,463
(Increase) decrease in:	10,873	9,432
Unconditional promises to give	333,023	(1,476,023)
Accounts receivable	(1,139)	
Prepaid expenses and other assets	(6,210)	6,442
Donated artwork	(25,239)	(10,000)
Increase (decrease) in:		
Accounts payable and accrued expenses	(264)	(3,853)
Deferred rent	(12,549)	10,499
Net Cash Used by Operating Activities	(403,254)	(25,040)
Cash Flows from Investing Activities		
Acquisition of property and equipment	(11,627)	(4,970)
Proceeds from sales of fixed assets		434
Net Cash Used by Investing Activities	(11,627)	(4,536)
Net decrease in cash and cash equivalents	(414,881)	(29,576)
Cash and cash equivalents, beginning of year	1,949,112	1,978,688
Cash and Cash Equivalents - End of Year	\$1,534,231	\$1,949,112

Statement of Activities

	2018		
	Without Donor Restrictions	With Donor Restrictions	Total
Revenue and Other Support			
Contributions	\$186,179	\$1,295,526	\$1,481,705
Fundraising benefits income	259,476		259,476
Less: Direct benefit expenses	(80,112)		(80,112)
Donated artwork, goods and services	123,150		123,150
Art sales, net of cost of goods sold	4,375		4,375
Other income	21,452		21,452
Interest Income	1,056	612	1,668
Net assets released from restrictions	1,826,382	(1,826,382)	
Total Revenue and Other Support	2,341,958	(530,244)	1,811,714
Expenses			
Program services			
HIV Program	640,329		640,329
Hepatitis C Virus Program	319,337		319,337
TB/HIV Program	1,127,736		1,127,736
Total Program Services	2,087,402		2,087,402
Supporting Services			
Management and General	262,119		262,119
Fundraising	163,942		163,942
Total Expenses	2,513,463		2,513,463
Increase (decrease) in net assets	(171,505)	(530,244)	(701,749)
Net assets, beginning of year, as previously reported	1,321,367	1,173,748	2,495,115
Prior period adjustments	586,172	875,311	1,461,483
Net assets, beginning of year, as restated	1,907,539	2,049,059	3,956,598
Net Assets, End of Year	\$1,736,034	\$1,518,815	\$3,254,849

Summary of 2018 Functional Expenses



\$100,000 or more

The Aurum Institute
Elton John AIDS
Foundation
Foundation for Innovative
New Diagnostics
Bill and Melinda Gates
Foundation
Stop TB Partnership
hosted by UNOPS
Veterans Affairs Medical
Center of Washington,
DC
ViiV Healthcare

\$50,000 to \$99,999

Broadway Cares / Equity
Fights AIDS
Ford Foundation
Nike, Inc.
Red Hot Organization

\$25,000 to \$49,999

Debs Foundation: Richard
A. and Barbara Knowles
Debs; Nick Debs
Elizabeth Glaser Pediatric
AIDS Foundation
Global Drug Facility via
Stop TB Partnership
Levi Strauss Foundation
Richard M. Lynn and
Joseph Evall
M•A•C AIDS Fund
Merck & Co.
Joy A. Tomchin

\$10,000 to \$24,999

amfAR, The Foundation
for AIDS Research
Annie Bennett Glenn
Fund in honor of P.
Forrest Williams, Jr.
Kevin and Neil Goetz
Marta Heflin Foundation
Janssen Therapeutics /
Johnson & Johnson
Health Care Systems
Robert W. Lennon and
Mark Gilrain
Robert Monteleone
The Elizabeth Taylor AIDS
Foundation

\$5,000 to \$9,999

Celeste B. Cooper
David Corkery
Monica Friel
Harvard University
Housing Works / Charles
King and Matthew
Bernardo
Barbara F. Hughes
Noel E.D. Kirnon and
Michael D. Paley in
honor of Rich Lynn
Alby P. Maccarone, Jr.
Dr. J. Michael McCune
and Dr. Karen Kaye
Smith-McCune
Bobby McLain and
Alberto Blanquel
David Rosenauer and Rex
Walker in honor of the

2018 RIAA Honorees
The Andrew D. Zacks
Foundation

\$2,500 to \$4,999

Amida Care / Doug Wirth
Jim Aquino
Ivy Arce
Katherine C. and Thomas
M. Ash III
Marisa Cardinale
Cepheid
Dr. Stephen M. Dillon in
honor of Tim Horn
John F. Duane and Mary
E. Northridge
The Gendal Family
Foundation in honor of
Monte Steinman
GMHC / Kelsey Louie
Judith M. and Richard
Harrington
Mark Harrington in honor
of Masha Gessen,
Peggy Hamburg, and
Joy Tomchin
Christina and Kenneth
Hecht in honor of Mark
Harrington
International Union
Against Tuberculosis
and Lung Disease
Jameel Jiwani
Peter Kukielski and J.
Drew Hodges
Dr. Jonathan LaPook in
honor of Kate Lear
Laura A. Morrison
Eddie Peltó in memory of
Daniel A. Volpe, Jr.
Dr. Bruce R. Schackman
and Edward K. Sikov
Mark M. Sexton and W.
Kirk Wallace
Sigal Family Foundation:
David Sigal and New
York State Senator Brad
Hoylman
John Voelcker

\$1,000 to \$2,499

AIDS Fonds Netherlands
Kim Allen-Niesen
Anonymous donations
AVAC / Mitchell Warren
Ian Bailey / Vivid Coffee
Margot and Robert J.
Bazell
Michael Beltran and
Timothy Ford
Jonathan Binstock
Andrew Bonacina
Bob Bronzo
Maria Bukhtoyarova /
Gaia Arts Foundation
Kenneth G. Castro, MD
Paul Cossu
Dick Dadey
Arianne Z. Dar / New
Ground Fund of Marin
Community Foundation
Nick Debs
Florence Derieux
John Deyling

Courtney E. DiMartino
Hon. Thomas K. Duane
Joseph Dunning
David France in memory
of Tim McCarthy
Garance Franke-Ruta
Barbara Gamson
Robert Gillard and James
Harrington in honor of
Monte Steinman
Global Health Strategies
Judy and Steven
Gluckstern in memory
of Michael Palm
Ron Goldberg and Joe
Chiplock
Karen and Steve Hirdt
David Hochberg
Foundation
Hon. James C. Hormel
Tim Hosking and Audrey
Sokoloff in honor
of Richard Lynn and
Joseph Evall
IAVI / Dr. Mark Feinberg
Johns Hopkins University
JPMorgan Chase Bank
NA
Emmy Kondo in memory
of Paul Corser
Babette Krolik and Sara
Rafsky in memory of
Bob Rafsky
Winston B. Layne
Josh Lehrer and Jeffrey
Seller Family
The Lesbian, Gay, Bisexual
and Transgender
Community Center
Michael K. Longacre
Médecins Sans Frontières
Mirla and George
Morrison
Sally Morrison and Tobias
Corser
Jason Osher and Richard
Schubel in memory
of Margie Garber-
Steinberg
Otsuka Novel Products
Partners In Health
Public Citizen Foundation
Karen Bronzo Rabb and
Jefferson Rabb
Lance Renner
Daniel Schaeffer
Andrew Schirmeister
in honor of Monte
Steinman
Evan Schwartz and Robert
Fitterman
Elisabeth Sherman
Scott Stangenes
Monte Steinman
Amanda Stoffel Mitnick
Madeline Warren
Susan Witherow
Suzanne Zissu

\$500 to \$999

Abramson Tzedakah Fund
/ Murray A. Abramson
Peter L. Allen in honor of
Bruce Schackman

Alain and Elsa Bankier
"Monte Steinman does
a great job for you!!!"
Jack Battaglia
Prof. Richard M. Buxbaum
and Catherine B.
Hartshorn in honor of
Mark Harrington
Paula and Mitchell Chalfin
Ellen Chesler in honor of
Jeff Mendoza
Steven M. and Denise
Chickery
Stephanie and Walter
Cowles
Paul L. Dietz
Steven M. Frank and Dr.
Elizabeth Powell
Andrew Friedman
Jennifer J. Furin, MD, PhD
New York State
Assemblymember
Deborah J. Glick
Aaron Glick
Roy M. 'Trip' Gulick, MD
Robert C. Henry
Michelle and Andre Doré
/ The InkLink Group
Rebecca Jordan-Young
in honor of Sally C.
Cooper
Burt Lazarin
David C. Levine
Chris Lipari
Loring McAlpin
Joseph McConnell and
Erik Haaagensen
Jeff Mendoza
Albert S. Messina in honor
of Richard Jacobs
Mount Sinai Institute for
Advanced Medicine
Daniel Ptacek
Clifford Richner
Walter Rieman in memory
of Tom Stoddard
Greig Sargeant
Jeffrey H. Schmitt and Dr.
Michael A. Petrilli, DDS,
MPH
Sarah F. and Roy E.
Schutzengel in memory
of Hartly Fleischmann
Screen Engine/ASI
David Shaw in honor of
Bob Bronzo
Ginny Shubert and David
Sipress
Jane Silver in honor of
Peggy Hamburg
Peter Staley
Marc Szafran
Dan Tietz / Bailey House
Barbara Toll in honor of
Jeff Mendoza
Robert Wheeler
James M. and Ruth E.
Wilder Foundation

\$250 to \$499

AIDS Treatment Activists
Coalition
Marc J. Berman
Scott P. Campbell

Richard Cardillo in
memory of Peter F.
Diffly Jr.
Dr. Charles C.J. Carpenter
Jr. and Mrs. Sally F.
Carpenter
Jeanie Carstensen
Lawrence Chanen
Mathew Chappell in
memory of Spencer
Cox
Deborah Cotton, MD,
in honor of Ida May
Lipsett
Megan Harrington and
Jonathan Creighton in
memory of Jay Kevin
Funk
Scott Dainton
Judith C. Davis-Fagan
Peter Morris Dixon
Monica Gerber
Leslie Asako Gladsjo
Edward B. Parran and
James F. Guidera
Paula Hartstein and
Jonathan Levin in honor
of Erica Lessem
Larry Iannotti in honor
of Richard Lynn and
Joseph Evall
Karyn Kaplan
Jason Lamb and Dr. Alan
Kristal
Margaret Lennon
Linda Liedtka
Massachusetts Medical
Society on behalf of Dr.
Helen Cox and Dr. Val
Mizrahi
Merle C. McCann, MD
Elaine and Glenn Mealy
Fernando J. Alva Mirás
Scott Newman
Kathleen O'Leary in honor
of Bob Bronzo
Pam A. Parker
Richard and Alice Pierson
Family Trust
Laura Pinsky in honor of
GHAP
Christina Previti
Sheila Reeves
David Rosen
Aditya Sankaranarayan
Peter Schamel
Dr. Jack Steever
Shivani Thaker
Keith S. Tobin, MD
Augusta Weiss
Elizabeth Strong Williams

plus donations from an
additional **215** generous
contributors

We would also like to
thank Zoe Leonard, Joy
Episalla, Diagonal Media,
King Displays, Print
Positive NY and SpotCo
for their generous in-kind
donations of goods and
services.

About TAG

Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.

TAG works to ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information.

We're science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.

TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end HIV, TB, and HCV.

Support TAG

TAG made many strides in the fight against HIV, HCV, and TB. We cannot lose momentum during this ever-changing political climate.

Make a gift to TAG and help us advocate for the needs of all people impacted by HIV, HCV, and TB.

Support TAG today: www.treatmentactiongroup.org/support.

Does your organization have a matching gifts program? Don't miss your chance to make a gift that keeps on giving. Complete and send us your company's matching gift form to double your contribution's impact!

Save the Date!
RESEARCH IN ACTION AWARDS
November 14, 2019
6 pm




★★★★
CHARITY NAVIGATOR
Four Star Charity

Thank You Board Officers

TAG's staff and board congratulate our two new Board Officers: Vice President, Bobby McLain, and Secretary, Rob Lennon. They take their place alongside our long-time Board President, Barbara Hughes, and Treasurer, Laura Morrison. We thank all four of our Officers for their dedication and service, and Barbara, Bobby, Laura, and Rob: you have our sincere gratitude for jobs well done.

TAG Limited Art Editions

Each year at its Research in Action Awards, TAG presents a new, limited edition work of art. Past artists include Zoe Leonard, Erica Baum, Rosalind Fox Solomon, Joy Episalla, Kate Shepherd, Nan Goldin, Robert Gober, Bill Jacobson, fierce pussy, Donald Moffett, Tony Feher, Carrie Yamaoka, David Armstrong, and Richard Renaldi.



Joy Episalla, 2015, Celestial Bodies, (40° 44' N x 73° 59' W), 1

TAG retains an inventory of many of the editions for sale to the public, and all proceeds benefit TAG's work. If you're interested in purchasing an edition or learning more about the available editions, detailed information can be found at <http://www.treatmentactiongroup.org/limited-art-editions>.

2019 BOARD OF DIRECTORS

PRESIDENT: Barbara Hughes

VICE PRESIDENT: Bobby McLain

TREASURER: Laura Morrison

SECRETARY: Robert W. Lennon

Jim Aquino
Frank Bua
Dick Dadey
Nick Debs
Joy Episalla
Kevin Goetz
Roy Gulick, M.D.
Jameel Jiwani
Richard Lynn, Ph.D., M.P.H.
Jeff Mendoza
Robert Monteleone
Eddie Pelto
David Sigal
Monte Steinman
Mrinal Vikram

STAFF

EXECUTIVE DIRECTOR:

Mark Harrington

DEPUTY EXECUTIVE DIRECTOR –

PROGRAMS: Erica Lessem

DEVELOPMENT MANAGER:

Jean Dorak

TB PROJECT CO-DIRECTOR:

Mike Frick

STATE AND LOCAL POLICY DIRECTOR:

Annette Gaudino

HCV PROJECT DIRECTOR: Bryn Gay

FINANCE MANAGER:

Christopher George

DIRECTOR OF FINANCE AND OPERATIONS:

Sabrina Guerrero-Morris

BASIC SCIENCE, VACCINES, AND

CURE PROJECT DIRECTOR:

Richard Jefferys

HIV PROJECT DIRECTOR:

Jeremiah Johnson

GOVERNMENT RELATIONS AND

POLICY OFFICER:

Elizabeth Lovinger

U.S. AND GLOBAL HEALTH POLICY

DIRECTOR: Suraj Madoori

ADMINISTRATOR:

Joseph McConnell

TB PROJECT CO-DIRECTOR:

Lindsay McKenna

COMMUNICATIONS MANAGER:

Dorrit Walsh



Treatment Action Group

www.treatmentactiongroup.org

90 Broad Street, Suite 2503
New York, NY 10004
Tel 212.253.7922, Fax 212.253.7923

tag@treatmentactiongroup.org

TAG is a nonprofit, tax-exempt
501(c)(3) organization.
EIN 13-3624785